Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · MicardisPlus

MicardisPlus 40 mg/12.5 mg tablets MicardisPlus 80 mg/12.5 mg tablets · Abschnitt 4.8 · PDF-Seite 11

HOS-110417 · Präparat HOS-093371

MedDRA System Adverse Reactions Frequency Organ Class MicardisPlus Telmisartana Hydrochlorothiazide Infections and Sepsis including infestations fatal outcome rare2 Bronchitis rare Pharyngitis rare Sinusitis rare Upper respiratory tract infection uncommon Urinary tract infection uncommon Cystitis uncommon Neoplasms Non-melanoma skin benign, cancer (Basal cell malignant and carcinoma and unspecified (incl. Squamous cell cysts and polyps) carcinoma) not known2 Blood and Anaemia uncommon lymphatic system Eosinophilia rare disorders Thrombocytopenia rare rare Thrombocytopenic purpura rare Aplastic anaemia not known Haemolytic anaemia very rare Bone marrow failure very rare Leukopenia very rare Agranulocytosis very rare Immune system Anaphylactic disorders reaction rare Hypersensitivity rare very rare Metabolism and Hypokalaemia uncommon very common nutrition Hyperuricaemia rare common disorders Hyponatraemia rare rare common Hyperkalaemia uncommon Hypoglycaemia (in diabetic patients) rare Hypomagnesaemia common Hypercalcaemia rare Alkalosis hypochloraemic very rare Decreased appetite common Hyperlipidaemia very common Hyperglycaemia rare Diabetes mellitus inadequate control rare Psychiatric Anxiety uncommon rare disorders Depression rare uncommon rare Insomnia rare uncommon Sleep disorders rare rare

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.